董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Benjamin F. McGraw, III | 男 | Independent Director | 71 | 35.42万美元 | 未持股 | 2020-04-14 |
| Julie H. McHugh | 女 | Independent Director | 55 | 32.67万美元 | 未持股 | 2020-04-14 |
| Richard Croarkin | 男 | Independent Director | 65 | 32.17万美元 | 未持股 | 2020-04-14 |
| Michael M. du Toit | 男 | Independent Director | 67 | 32.42万美元 | 未持股 | 2020-04-14 |
| David W. Gryska | 男 | Independent Director | 64 | 32.62万美元 | 未持股 | 2020-04-14 |
| Murray A. Goldberg | 男 | Independent Director | 75 | 33.17万美元 | 未持股 | 2020-04-14 |
| Vicente Anido, Jr. | 男 | Chief Executive Officer and Chairman of the Board | 67 | 552.97万美元 | 未持股 | 2020-04-14 |
| Gerald D. Cagle | 男 | Independent Director | 75 | 32.92万美元 | 未持股 | 2020-04-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John W. LaRocca | 男 | General Counsel and Assistant Secretary | 55 | 252.44万美元 | 未持股 | 2020-04-14 |
| David A. Hollander | 男 | Chief Research and Development Officer | 46 | 未披露 | 未持股 | 2020-04-14 |
| Vicente Anido, Jr. | 男 | Chief Executive Officer and Chairman of the Board | 67 | 552.97万美元 | 未持股 | 2020-04-14 |
| Casey C. Kopczynski | 男 | Chief Scientific Officer | 58 | 196.59万美元 | 未持股 | 2020-04-14 |
| Thomas A. Mitro | 男 | President and Chief Operating Officer | 62 | 279.30万美元 | 未持股 | 2020-04-14 |
| Richard J. Rubino | 男 | Chief Financial Officer, Secretary and Treasurer | 62 | 246.54万美元 | 未持股 | 2020-04-14 |
董事简历
中英对照 | 中文 | 英文- Benjamin F. McGraw, III
-
Benjamin F. McGraw, III， 自2020年10月起担任董事会主席。McGraw博士是Perfe Therapeutics的执行主席，Perfe Therapeutics是一家临床阶段的生物制药公司，致力于降低失明的发生率。他还是TheraVida的董事，这是一家专注于皮肤病疗法的私营制药公司。自2014年以来，McGraw博士一直担任Auration Biotech的执行董事长，该公司是一家私营生物技术公司，专注于耳鼻喉疾病的再生蛋白和其他疗法。McGraw博士是Aerie医药董事会的首席独立董事，该公司是一家上市制药公司，专注于青光眼和其他眼睛前后部疾病的新疗法。他还是Trefoil Therapeutics的执行董事长，这是一家私营生物制药公司，专注于开发一种工程蛋白，作为角膜内皮营养不良和上皮疾病的再生治疗方法。Previoly，McGraw博士曾担任投资咨询公司Long Shadows Asset Management，LLC的管理成员；上市基因治疗公司Valentis的董事长、总裁兼首席执行官；上市制药公司Allergan的企业发展副总裁；以及两家上市制药公司Marion Laboratories和Marion Merrell Dow的发展副总裁。McGraw博士在田纳西大学健康科学中心获得了学士学位和药学博士学位，并在那里完成了临床实习住院医师。
Benjamin F. McGraw, III has served as a member of board of directors since inception in April 2020 and has served as Chairman of the Board since May 2020. Prior to joining , Mr. McGraw served as President and Chief Executive Officer of Dermira from 2010 to 2020. Prior to Dermira, Mr. McGraw served as President and Chief Executive Officer of Peplin, a position he held from 2008 through 2009 when Peplin was acquired by LEO Pharma. Peplin foced on an innovative product (Picato) that was approved by the FDA for e in the treatment of actinic keratosis. Prior to Peplin, he was CEO of Neosil, a development stage dermatology pharmaceutical company acquired by Peplin in 2008. Mr. McGraw received his Pharm.D. from the University of California, San Francisco. - Benjamin F. McGraw, III， 自2020年10月起担任董事会主席。McGraw博士是Perfe Therapeutics的执行主席，Perfe Therapeutics是一家临床阶段的生物制药公司，致力于降低失明的发生率。他还是TheraVida的董事，这是一家专注于皮肤病疗法的私营制药公司。自2014年以来，McGraw博士一直担任Auration Biotech的执行董事长，该公司是一家私营生物技术公司，专注于耳鼻喉疾病的再生蛋白和其他疗法。McGraw博士是Aerie医药董事会的首席独立董事，该公司是一家上市制药公司，专注于青光眼和其他眼睛前后部疾病的新疗法。他还是Trefoil Therapeutics的执行董事长，这是一家私营生物制药公司，专注于开发一种工程蛋白，作为角膜内皮营养不良和上皮疾病的再生治疗方法。Previoly，McGraw博士曾担任投资咨询公司Long Shadows Asset Management，LLC的管理成员；上市基因治疗公司Valentis的董事长、总裁兼首席执行官；上市制药公司Allergan的企业发展副总裁；以及两家上市制药公司Marion Laboratories和Marion Merrell Dow的发展副总裁。McGraw博士在田纳西大学健康科学中心获得了学士学位和药学博士学位，并在那里完成了临床实习住院医师。
- Benjamin F. McGraw, III has served as a member of board of directors since inception in April 2020 and has served as Chairman of the Board since May 2020. Prior to joining , Mr. McGraw served as President and Chief Executive Officer of Dermira from 2010 to 2020. Prior to Dermira, Mr. McGraw served as President and Chief Executive Officer of Peplin, a position he held from 2008 through 2009 when Peplin was acquired by LEO Pharma. Peplin foced on an innovative product (Picato) that was approved by the FDA for e in the treatment of actinic keratosis. Prior to Peplin, he was CEO of Neosil, a development stage dermatology pharmaceutical company acquired by Peplin in 2008. Mr. McGraw received his Pharm.D. from the University of California, San Francisco.
- Julie H. McHugh
-
Julie H. McHugh，她曾担任Lantheus Holdings， Inc.的成员。自2015年6月起担任董事会成员。她曾担任Endo Health Solutions， Inc.的首席运营官（2010年3月至2013年5月退休），负责专业制药和仿制药业务。在此之前，她是Nora Therapeutics， Inc.（一家风险资本支持的生物技术初创公司，专注于开发治疗不孕症的新疗法）的首席执行官。此前，她曾担任Johnson & Johnson全球病毒学业务部门的公司集团主席，在此之前，她曾担任强生子公司Centocor， Inc.的总裁。在此职位上，她负责监督几种产品的开发和发布，包括Remicade infliximab， Prezista （darunavir）和intelligence （etravirine）。加入Centocor之前，她在Astra-Merck Inc.领导胃肠药物Prilosec（奥美拉唑）的营销传播。她目前担任Ironwood Pharmaceuticals， Inc.的董事会主席，以及Lantheus Holdings， Inc.、New Xellia Group A/S和Trevena Pharmaceuticals， Inc.的董事会成员。她曾担任the Biotechnology Industry Organization （BIO）、the New England Healthcare Institute （NEHI）、the Pennsylvania Biotechnology Association、EPIRUS Biopharmaceuticals, Inc.和ViroPharma Inc.的董事会成员。她在St. Joseph大学获得工商管理硕士学位，在Pennsylvania State大学获得学士学位。
Julie H. McHugh,most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from 2010 through 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses.Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc.Before that she served as company group chair for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade (infliximab) and she was responsible for oversight of a research and development portfolio including compounds targeting autoimmune diseases, HIV, hepatitis C, and tuberculosis.Prior to joining Centocor, Inc., Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc.Ms. McHugh currently serves on the board of directors of Lantheus Holdings, Inc. (Nasdaq: LNTH), a public company, and Xellia Pharmaceuticals ApS, a privately held company. She also serves on the strategic advisory board for HealthCare Royalty Partners and the board of visitors for the Smeal College of Business of Pennsylvania State University. She previously served on the board of directors for Aerie Pharmaceuticals, Inc., Trevena, Inc., ViroPharma Inc., Epirus Biopharmaceuticals, Inc., Evelo Biosciences, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute.Ms. McHugh received her M.B.A. degree from St. Joseph's University and her B.S. degree from Pennsylvania State University. - Julie H. McHugh，她曾担任Lantheus Holdings， Inc.的成员。自2015年6月起担任董事会成员。她曾担任Endo Health Solutions， Inc.的首席运营官（2010年3月至2013年5月退休），负责专业制药和仿制药业务。在此之前，她是Nora Therapeutics， Inc.（一家风险资本支持的生物技术初创公司，专注于开发治疗不孕症的新疗法）的首席执行官。此前，她曾担任Johnson & Johnson全球病毒学业务部门的公司集团主席，在此之前，她曾担任强生子公司Centocor， Inc.的总裁。在此职位上，她负责监督几种产品的开发和发布，包括Remicade infliximab， Prezista （darunavir）和intelligence （etravirine）。加入Centocor之前，她在Astra-Merck Inc.领导胃肠药物Prilosec（奥美拉唑）的营销传播。她目前担任Ironwood Pharmaceuticals， Inc.的董事会主席，以及Lantheus Holdings， Inc.、New Xellia Group A/S和Trevena Pharmaceuticals， Inc.的董事会成员。她曾担任the Biotechnology Industry Organization （BIO）、the New England Healthcare Institute （NEHI）、the Pennsylvania Biotechnology Association、EPIRUS Biopharmaceuticals, Inc.和ViroPharma Inc.的董事会成员。她在St. Joseph大学获得工商管理硕士学位，在Pennsylvania State大学获得学士学位。
- Julie H. McHugh,most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from 2010 through 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses.Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc.Before that she served as company group chair for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade (infliximab) and she was responsible for oversight of a research and development portfolio including compounds targeting autoimmune diseases, HIV, hepatitis C, and tuberculosis.Prior to joining Centocor, Inc., Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc.Ms. McHugh currently serves on the board of directors of Lantheus Holdings, Inc. (Nasdaq: LNTH), a public company, and Xellia Pharmaceuticals ApS, a privately held company. She also serves on the strategic advisory board for HealthCare Royalty Partners and the board of visitors for the Smeal College of Business of Pennsylvania State University. She previously served on the board of directors for Aerie Pharmaceuticals, Inc., Trevena, Inc., ViroPharma Inc., Epirus Biopharmaceuticals, Inc., Evelo Biosciences, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute.Ms. McHugh received her M.B.A. degree from St. Joseph's University and her B.S. degree from Pennsylvania State University.
- Richard Croarkin
-
Richard Croarkin自2016年2月起一直担任公司的董事。2007年至2010年， Croarkin先生担任高级副总裁，首席财务官以及Alcon, Inc.的企业战略官。Alcon公司是一家公共眼科制药和医疗设备公司。2011年至2013年年初，Croarkin先生担任Nestle Health Science, S.A.的首席财务官。Nestle Health Science, S.A.是Nestle公司的一个分部，专注于慢性疾病医疗化营养方案。 Croarkin先生于2013年初退休。Croarkin先生目前是Aerie Pharmaceuticals, Inc.的董事会和审计委员会的成员。Aerie制药公司是一家公众临床分期制药公司。 Croarkin先生偶尔也是纳斯达克上市资格委员会专家小组成员，已经被纳斯达克摘牌，收到NASDAQ的通知。 Croarkin先生获得Georgetown University经济学学士学位和University of Connecticut金融工商管理硕士学位。
Richard Croarkin has served as a member of Aerie Pharmaceuticals, Inc.'s Board since May 2015. Mr. Croarkin previously was Chief Financial Officer of Nestle Health Science, a division of Nestle focused on medicalized nutrition solutions for chronic medical conditions, from December 2010 to February 2013. From 2007 to 2010 Mr. Croarkin was Senior Vice President, Chief Financial Officer, and Corporate Strategy Officer at Alcon, which had annual sales of $7.1 billion and was the world''s leading ophthalmic pharmaceutical and medical device company before its acquisition by Novartis for $50 billion. In 2008 and 2009 Mr. Croarkin also served as a director on the supervisory board of the German publicly-traded company, WaveLight A.G., which manufactures and globally markets laser and diagnostic systems for refractive eye surgery. Previously, Mr. Croarkin was Executive Vice President and Chief Financial Officer of Nestle Waters North America, overseeing the finances of a business unit that grew to $4.4 billion in sales. Before joining Nestle, Mr. Croarkin worked for Pepsico Incorporated, where he served in a number of senior financial positions around the world, including as Chief Financial Officer of Pepsi Latin America and Pepsi Canada. Mr. Croarkin started his career with AMAX, Inc., where he worked in treasury, corporate development and planning. Mr. Croarkin currently serves as a member of the board of directors of Clearside Biomedical, a company advancing eye disease therapies by delivering drugs to the suprachoroidal space via a proprietary microinjector. He also serves on occasion as a panelist on the NASDAQ Listing Qualifications Panel. In 2018 Mr. Croarkin was elected to the Board of Waveny LifeCare Network, Inc., a not-for-profit nursing home and healthcare provider for Southwestern Connecticut's senior population. Mr. Croarkin received his B.A. in Economics from Georgetown University and his M.B.A. in Finance from the University of Connecticut. - Richard Croarkin自2016年2月起一直担任公司的董事。2007年至2010年， Croarkin先生担任高级副总裁，首席财务官以及Alcon, Inc.的企业战略官。Alcon公司是一家公共眼科制药和医疗设备公司。2011年至2013年年初，Croarkin先生担任Nestle Health Science, S.A.的首席财务官。Nestle Health Science, S.A.是Nestle公司的一个分部，专注于慢性疾病医疗化营养方案。 Croarkin先生于2013年初退休。Croarkin先生目前是Aerie Pharmaceuticals, Inc.的董事会和审计委员会的成员。Aerie制药公司是一家公众临床分期制药公司。 Croarkin先生偶尔也是纳斯达克上市资格委员会专家小组成员，已经被纳斯达克摘牌，收到NASDAQ的通知。 Croarkin先生获得Georgetown University经济学学士学位和University of Connecticut金融工商管理硕士学位。
- Richard Croarkin has served as a member of Aerie Pharmaceuticals, Inc.'s Board since May 2015. Mr. Croarkin previously was Chief Financial Officer of Nestle Health Science, a division of Nestle focused on medicalized nutrition solutions for chronic medical conditions, from December 2010 to February 2013. From 2007 to 2010 Mr. Croarkin was Senior Vice President, Chief Financial Officer, and Corporate Strategy Officer at Alcon, which had annual sales of $7.1 billion and was the world''s leading ophthalmic pharmaceutical and medical device company before its acquisition by Novartis for $50 billion. In 2008 and 2009 Mr. Croarkin also served as a director on the supervisory board of the German publicly-traded company, WaveLight A.G., which manufactures and globally markets laser and diagnostic systems for refractive eye surgery. Previously, Mr. Croarkin was Executive Vice President and Chief Financial Officer of Nestle Waters North America, overseeing the finances of a business unit that grew to $4.4 billion in sales. Before joining Nestle, Mr. Croarkin worked for Pepsico Incorporated, where he served in a number of senior financial positions around the world, including as Chief Financial Officer of Pepsi Latin America and Pepsi Canada. Mr. Croarkin started his career with AMAX, Inc., where he worked in treasury, corporate development and planning. Mr. Croarkin currently serves as a member of the board of directors of Clearside Biomedical, a company advancing eye disease therapies by delivering drugs to the suprachoroidal space via a proprietary microinjector. He also serves on occasion as a panelist on the NASDAQ Listing Qualifications Panel. In 2018 Mr. Croarkin was elected to the Board of Waveny LifeCare Network, Inc., a not-for-profit nursing home and healthcare provider for Southwestern Connecticut's senior population. Mr. Croarkin received his B.A. in Economics from Georgetown University and his M.B.A. in Finance from the University of Connecticut.
- Michael M. du Toit
-
Michael M. du Toit，2015年6月以来，他担任我们的董事会成员。2015年2月以来，他一直担任Everyday Health的总裁。加入Everyday Health之前，他曾担任Publicis Healthcare Communications Group（世界上第三大广告和媒体公司）的多种职务，包括全球集团总裁（从2012年3月到2015年2月）。他曾担任其它公司的多种高级执行职务（从2006年7月到2012年2月），包括Digitas Health的总裁，在那里他曾担任Digitas Health Media、RazorFish Health的创始成员。他也曾担任第一营销机构的执行职务，包括Grey Advertising、BBD&O 、Ventiv Health Communications。他也曾担任制药公司的高级营销职务，其中包括GlaxoSmithKline、Boehringer Ingelheim Pharmaceuticals。任职Glaxo公司期间，他曾担任营销副总裁，随后推出了数款重磅药品，包括Serevent （沙美特罗）、Flonase （氟替卡松鼻）。他此前曾担任the National Pharmaceutical Council、Pharmaceutical Advertising Council、Advertising Club of Fairfield、Advertising Club of New York、Editorial Board of Medical Marketing and Media, Prescription Drug Advertising Coalition、Triangle Advertising Federation的成员。他的职业生涯始于任职Unilever（一个消费产品公司）。他持有Stellenbosch University（位于南非）的经济学和市场营销学士学位。
Michael M. du Toit has served as a member of our Board since June 2015. In December 2017 Mr. du Toit was appointed Group President, Chief Growth Officer of Publicis Health, a division of Publicis Groupe, S.A., the third largest advertising and media company in the world. Mr. du Toit previously served as President and Chief Client Officer of Everyday Health since February 2015. Prior to this, Mr. du Toit served in various positions, including Global Group President of Publicis Healthcare Communications Group from March 2012 to February 2015. Mr. du Toit held various senior executive positions from July 2006 to February 2012 at other companies, including President of Digitas Health, where he was a founding member, Digitas Health Media and RazorFish Health. Mr. du Toit also has held executive roles at premier marketing agencies including Grey Advertising, BBD&O and Ventiv Health Communications. Mr. du Toit also held senior marketing positions at pharmaceutical companies such as GlaxoSmithKline and Boehringer Ingelheim Pharmaceuticals. At Glaxo, as Vice President of Marketing, Mr. du Toit launched several blockbuster pharmaceutical products, including Serevent® salmeterol and Flonase® (fluticasone nasal). Mr. du Toit previously served as member of the National Pharmaceutical Council, Pharmaceutical Advertising Council, Advertising Club of Fairfield, Advertising Club of New York, Editorial Board of Medical Marketing and Media, Prescription Drug Advertising Coalition, and Triangle Advertising Federation. He started his career at Unilever, a consumer products company. Mr. du Toit received a B.S. in Economics and Marketing from Stellenbosch University in South Africa. - Michael M. du Toit，2015年6月以来，他担任我们的董事会成员。2015年2月以来，他一直担任Everyday Health的总裁。加入Everyday Health之前，他曾担任Publicis Healthcare Communications Group（世界上第三大广告和媒体公司）的多种职务，包括全球集团总裁（从2012年3月到2015年2月）。他曾担任其它公司的多种高级执行职务（从2006年7月到2012年2月），包括Digitas Health的总裁，在那里他曾担任Digitas Health Media、RazorFish Health的创始成员。他也曾担任第一营销机构的执行职务，包括Grey Advertising、BBD&O 、Ventiv Health Communications。他也曾担任制药公司的高级营销职务，其中包括GlaxoSmithKline、Boehringer Ingelheim Pharmaceuticals。任职Glaxo公司期间，他曾担任营销副总裁，随后推出了数款重磅药品，包括Serevent （沙美特罗）、Flonase （氟替卡松鼻）。他此前曾担任the National Pharmaceutical Council、Pharmaceutical Advertising Council、Advertising Club of Fairfield、Advertising Club of New York、Editorial Board of Medical Marketing and Media, Prescription Drug Advertising Coalition、Triangle Advertising Federation的成员。他的职业生涯始于任职Unilever（一个消费产品公司）。他持有Stellenbosch University（位于南非）的经济学和市场营销学士学位。
- Michael M. du Toit has served as a member of our Board since June 2015. In December 2017 Mr. du Toit was appointed Group President, Chief Growth Officer of Publicis Health, a division of Publicis Groupe, S.A., the third largest advertising and media company in the world. Mr. du Toit previously served as President and Chief Client Officer of Everyday Health since February 2015. Prior to this, Mr. du Toit served in various positions, including Global Group President of Publicis Healthcare Communications Group from March 2012 to February 2015. Mr. du Toit held various senior executive positions from July 2006 to February 2012 at other companies, including President of Digitas Health, where he was a founding member, Digitas Health Media and RazorFish Health. Mr. du Toit also has held executive roles at premier marketing agencies including Grey Advertising, BBD&O and Ventiv Health Communications. Mr. du Toit also held senior marketing positions at pharmaceutical companies such as GlaxoSmithKline and Boehringer Ingelheim Pharmaceuticals. At Glaxo, as Vice President of Marketing, Mr. du Toit launched several blockbuster pharmaceutical products, including Serevent® salmeterol and Flonase® (fluticasone nasal). Mr. du Toit previously served as member of the National Pharmaceutical Council, Pharmaceutical Advertising Council, Advertising Club of Fairfield, Advertising Club of New York, Editorial Board of Medical Marketing and Media, Prescription Drug Advertising Coalition, and Triangle Advertising Federation. He started his career at Unilever, a consumer products company. Mr. du Toit received a B.S. in Economics and Marketing from Stellenbosch University in South Africa.
- David W. Gryska
-
David W. Gryska，2005年3月起任公司董事。2012年5月至12月，他担任上市生物科技公司Myrexis Inc.首席运营官，2012年8月至12月任临时首席执行官。2006年12月至2010年10月，他担任Celgene Corporation高级副总裁和首席财务官。2004年10月至2006年12月，他担任Strategic Consulting Group的主管，向早期的生物科技公司提供战略咨询。2000年11月至2004年10月期间，他在生物制药公司Scios, Inc.担任高级副总裁和首席财务官。2003年Scios被Johnson & Johnson收购。1993至1998年12月，让担任医疗设备公司Cardiac Pathways Corporation的财务副总裁和首席财务官。加入Cardiac Pathways前，他是会计师事务所Ernst & Young LLP的合伙人。在Ernst & Young LLP任职11年期间，他专注于科技行业，尤其是生物科技和医疗保健公司。他获有Loyola University 会计与金融学学士学位，Golden Gate University的工商管理硕士学位。除Seattle Genetics外，他也在Aerie Pharmaceuticals, Inc.、Argos Therapeutics, Inc.以及 PDL BioPharma, Inc.的董事会任职。
David W. Gryska,Incyte Corporation, a publicly-traded biopharmaceutical company,Executive Vice President and Chief Financial Officer 2014-2018; retired.Myrexis, Inc., a publicly-traded biotechnology company,Chief Operating Officer and Interim Chief Executive Officer -2012 Corporation, a publicly-traded biopharmaceutical company,Senior Vice President and Chief Financial Officer (2006-2010). PDL BioPharma, Inc., Aerie Pharmaceuticals, Inc.. - David W. Gryska，2005年3月起任公司董事。2012年5月至12月，他担任上市生物科技公司Myrexis Inc.首席运营官，2012年8月至12月任临时首席执行官。2006年12月至2010年10月，他担任Celgene Corporation高级副总裁和首席财务官。2004年10月至2006年12月，他担任Strategic Consulting Group的主管，向早期的生物科技公司提供战略咨询。2000年11月至2004年10月期间，他在生物制药公司Scios, Inc.担任高级副总裁和首席财务官。2003年Scios被Johnson & Johnson收购。1993至1998年12月，让担任医疗设备公司Cardiac Pathways Corporation的财务副总裁和首席财务官。加入Cardiac Pathways前，他是会计师事务所Ernst & Young LLP的合伙人。在Ernst & Young LLP任职11年期间，他专注于科技行业，尤其是生物科技和医疗保健公司。他获有Loyola University 会计与金融学学士学位，Golden Gate University的工商管理硕士学位。除Seattle Genetics外，他也在Aerie Pharmaceuticals, Inc.、Argos Therapeutics, Inc.以及 PDL BioPharma, Inc.的董事会任职。
- David W. Gryska,Incyte Corporation, a publicly-traded biopharmaceutical company,Executive Vice President and Chief Financial Officer 2014-2018; retired.Myrexis, Inc., a publicly-traded biotechnology company,Chief Operating Officer and Interim Chief Executive Officer -2012 Corporation, a publicly-traded biopharmaceutical company,Senior Vice President and Chief Financial Officer (2006-2010). PDL BioPharma, Inc., Aerie Pharmaceuticals, Inc..
- Murray A. Goldberg
-
Murray A. Goldberg，自2013年8月起担任本公司董事。自2013年10月起，他担任 Regeneron Pharmaceuticals的高级行政副总裁，自2000年1月起担任副秘书；1995年3月至2013年10月，他担任首席财务官兼高级财务与行政副总裁；1995年3月至2012年10月，担任财务总管。加入Regeneron之前，他从1991年2月起，担任生物制药公司PharmaGenics Inc的财务副总裁，财务总管兼首席财务官；1991年5月起，担任董事。1987-1990，他担任大通曼哈顿银行结构性融资部总经理；1973-1987，他在American Cyanimid Company财务与企业发展部担任了多个管理性职位，这是一家多元化的工业公司。他获得了芝加哥大学工商管理硕士学位，伦敦经济学院经济学硕士学位。
Murray A. Goldberg has served as a member of our Board since August 2013. Mr. Goldberg retired from Regeneron Pharmaceuticals, Inc. at the end of 2015. At Regeneron Pharmaceuticals, Inc., Mr. Goldberg served as Senior Vice President, Administration, from October 2013 to March 2015 and as Chief Financial Officer and Senior Vice President, Finance and Administration, from March 1995 to October 2013. Mr. Goldberg also served as Treasurer from March 1995 to October 2012. Mr. Goldberg currently serves on the board of directors of Teva Pharmaceutical Industries Ltd. and Ayala Pharmaceuticals Inc. Prior to joining Regeneron Pharmaceuticals Inc., Mr. Goldberg was Vice President, Finance, Treasurer, and Chief Financial Officer of PharmaGenics Inc., a biotechnology company, from February 1991 and a director of PharmaGenics Inc. from May 1991. From 1987 to 1990 Mr. Goldberg was Managing Director, Structured Finance Group at the Chase Manhattan Bank, N.A. and from 1973 to 1987 he served in various managerial positions in finance and corporate development at American Cyanamid Company, a Fortune 100 diversified industrial company. Mr. Goldberg received his M.B.A. from the University of Chicago and a M.Sc. in Economics from the London School of Economics. - Murray A. Goldberg，自2013年8月起担任本公司董事。自2013年10月起，他担任 Regeneron Pharmaceuticals的高级行政副总裁，自2000年1月起担任副秘书；1995年3月至2013年10月，他担任首席财务官兼高级财务与行政副总裁；1995年3月至2012年10月，担任财务总管。加入Regeneron之前，他从1991年2月起，担任生物制药公司PharmaGenics Inc的财务副总裁，财务总管兼首席财务官；1991年5月起，担任董事。1987-1990，他担任大通曼哈顿银行结构性融资部总经理；1973-1987，他在American Cyanimid Company财务与企业发展部担任了多个管理性职位，这是一家多元化的工业公司。他获得了芝加哥大学工商管理硕士学位，伦敦经济学院经济学硕士学位。
- Murray A. Goldberg has served as a member of our Board since August 2013. Mr. Goldberg retired from Regeneron Pharmaceuticals, Inc. at the end of 2015. At Regeneron Pharmaceuticals, Inc., Mr. Goldberg served as Senior Vice President, Administration, from October 2013 to March 2015 and as Chief Financial Officer and Senior Vice President, Finance and Administration, from March 1995 to October 2013. Mr. Goldberg also served as Treasurer from March 1995 to October 2012. Mr. Goldberg currently serves on the board of directors of Teva Pharmaceutical Industries Ltd. and Ayala Pharmaceuticals Inc. Prior to joining Regeneron Pharmaceuticals Inc., Mr. Goldberg was Vice President, Finance, Treasurer, and Chief Financial Officer of PharmaGenics Inc., a biotechnology company, from February 1991 and a director of PharmaGenics Inc. from May 1991. From 1987 to 1990 Mr. Goldberg was Managing Director, Structured Finance Group at the Chase Manhattan Bank, N.A. and from 1973 to 1987 he served in various managerial positions in finance and corporate development at American Cyanamid Company, a Fortune 100 diversified industrial company. Mr. Goldberg received his M.B.A. from the University of Chicago and a M.Sc. in Economics from the London School of Economics.
- Vicente Anido, Jr.
-
自2013年2月，Vicente Anido, Jr.担任公司董事。目前，他是Aerie Pharmaceuticals主席兼首席执行官，一家上市发展阶段公司，其集中在眼科领域。他是Ista Pharmaceuticals的前任总裁、首席执行官兼董事，该公司成立于2012年。在加入Ista Pharmaceuticals之前，从2000年到2001年，他担任Windamere Venture Partners的普通合伙人。从1996年到1999年，他担任CombiChem的总裁兼首席执行官，一家药物发现公司。从1993年到1996年，他担任Allergan美国地区总裁，负责北美和南美的商业运作。加入Allergan之前，他在Marion Laboratories and Marion Merrell Dow工作17年，包括Marion美国处方产品部门的业务管理副总裁。
Vicente Anido, Jr. has served as our Chief Executive Officer since July 2013 and as Chairman of our Board since April 2013. Dr. Anido is the former President, Chief Executive Officer and Director of ISTA Pharmaceuticals, Inc., which was acquired by Bausch + Lomb, Inc. in 2012. Prior to joining ISTA Pharmaceuticals, Dr. Anido served as General Partner of Windamere Venture Partners from 2000 to 2001. From 1996 to 1999 Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company. From 1993 to 1996 Dr. Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan’s commercial operations for North and South America. Prior to joining Allergan, Dr. Anido spent 17 years at Marion Laboratories and Marion Merrell Dow, Inc., including as Vice President, Business Management of Marion’s U.S. Prescription Products Division. Dr. Anido previously served as a member of the board of directors of QLT Inc. from 2012 to 2013 Depomed, Inc. from February 2013 to May 2016 and Nicox S.A. from June 2013 to June 2014. In addition, from 2002 to 2008 Dr. Anido served as a member of the board of directors of Apria Healthcare, Inc. Dr. Anido holds a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City. - 自2013年2月，Vicente Anido, Jr.担任公司董事。目前，他是Aerie Pharmaceuticals主席兼首席执行官，一家上市发展阶段公司，其集中在眼科领域。他是Ista Pharmaceuticals的前任总裁、首席执行官兼董事，该公司成立于2012年。在加入Ista Pharmaceuticals之前，从2000年到2001年，他担任Windamere Venture Partners的普通合伙人。从1996年到1999年，他担任CombiChem的总裁兼首席执行官，一家药物发现公司。从1993年到1996年，他担任Allergan美国地区总裁，负责北美和南美的商业运作。加入Allergan之前，他在Marion Laboratories and Marion Merrell Dow工作17年，包括Marion美国处方产品部门的业务管理副总裁。
- Vicente Anido, Jr. has served as our Chief Executive Officer since July 2013 and as Chairman of our Board since April 2013. Dr. Anido is the former President, Chief Executive Officer and Director of ISTA Pharmaceuticals, Inc., which was acquired by Bausch + Lomb, Inc. in 2012. Prior to joining ISTA Pharmaceuticals, Dr. Anido served as General Partner of Windamere Venture Partners from 2000 to 2001. From 1996 to 1999 Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company. From 1993 to 1996 Dr. Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan’s commercial operations for North and South America. Prior to joining Allergan, Dr. Anido spent 17 years at Marion Laboratories and Marion Merrell Dow, Inc., including as Vice President, Business Management of Marion’s U.S. Prescription Products Division. Dr. Anido previously served as a member of the board of directors of QLT Inc. from 2012 to 2013 Depomed, Inc. from February 2013 to May 2016 and Nicox S.A. from June 2013 to June 2014. In addition, from 2002 to 2008 Dr. Anido served as a member of the board of directors of Apria Healthcare, Inc. Dr. Anido holds a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City.
- Gerald D. Cagle
-
Gerald D. Cagle，自2013年9月起担任本公司董事。他现任致力于阿尔茨海默氏病的诊断的公司 Cognoptix, lnc的首席运营官。他还是平台药物递送公司 GrayBug, LLC的高级顾问及业务发展总监公司。此前，1997-2008，他曾担任Alcon Laboratories 研发部高级副总裁，并自2006年担任首席科学家。他目前担任Clearside Biomedical的董事，一个提供葡萄膜炎脉络膜上腔的抗炎疗法的公司；也是研究干眼病新疗法的公司 AB2 Bio的董事。他现任 Wilmer Eye Institute 顾问委员会和ARVO基金会董事会的成员。他获得了韦兰学院学士学位，以及北德州大学的硕士和博士学位。
Gerald D. Cagle has served as a member of our Board since September 2013. Dr. Cagle was appointed Senior Vice President of Research & Development at Alcon Laboratories Inc. in 1997 a position he held until 2009. From 2009 until his retirement in 2013 Dr. Cagle held the position of Chief Operating Officer at Cognoptix, a company focused on the diagnosis of Alzheimer's disease. Dr. Cagle also serves on the board of directors of GrayBug, Inc., Nacuity, Pharmaceuticals, Inc., and AB2 Bio Ltd. Dr. Cagle received his B.S. from Wayland College, earned both his M.S. and Ph.D. from the University of North Texas and completed the Program for Management Development at Harvard Business School. - Gerald D. Cagle，自2013年9月起担任本公司董事。他现任致力于阿尔茨海默氏病的诊断的公司 Cognoptix, lnc的首席运营官。他还是平台药物递送公司 GrayBug, LLC的高级顾问及业务发展总监公司。此前，1997-2008，他曾担任Alcon Laboratories 研发部高级副总裁，并自2006年担任首席科学家。他目前担任Clearside Biomedical的董事，一个提供葡萄膜炎脉络膜上腔的抗炎疗法的公司；也是研究干眼病新疗法的公司 AB2 Bio的董事。他现任 Wilmer Eye Institute 顾问委员会和ARVO基金会董事会的成员。他获得了韦兰学院学士学位，以及北德州大学的硕士和博士学位。
- Gerald D. Cagle has served as a member of our Board since September 2013. Dr. Cagle was appointed Senior Vice President of Research & Development at Alcon Laboratories Inc. in 1997 a position he held until 2009. From 2009 until his retirement in 2013 Dr. Cagle held the position of Chief Operating Officer at Cognoptix, a company focused on the diagnosis of Alzheimer's disease. Dr. Cagle also serves on the board of directors of GrayBug, Inc., Nacuity, Pharmaceuticals, Inc., and AB2 Bio Ltd. Dr. Cagle received his B.S. from Wayland College, earned both his M.S. and Ph.D. from the University of North Texas and completed the Program for Management Development at Harvard Business School.
高管简历
中英对照 | 中文 | 英文- John W. LaRocca
JohnW.LaRocca自2018年2月起担任我们的总法律顾问。2015年3月至2018年1月，拉罗卡先生担任EaglePharmaceuticals，Inc.执行Vice President and General Counsel从2005年12月到2012年12月，Larocca先生担任Actavis Inc.的美洲首席法律官，从2013年1月到2014年12月，担任Actavis plc的副总法律顾问。在此之前，LaRocca从2000年9月到2005年12月担任PurePac Pharmaceuticals和Alpharma Pharmaceuticals美国仿制药部门法律顾问。此前，LaRocca先生与Parker Duryee Rosoff&Haft；Christie&Viener；和Webster&Sheffield在纽约实践公司法和商业法。LaRocca先生在哥伦比亚学院（Columbia College）获得学士学位，在哥伦比亚法学院（Columbia Law School）获得法学博士学位。
John W. LaRocca has served as our General Counsel since February 2018. From March 2015 through January 2018 Mr. LaRocca served as Executive Vice President and General Counsel for Eagle Pharmaceuticals, Inc. From December 2005 through December 2012 Mr. LaRocca was Chief Legal Officer for the Americas for Actavis Inc. and from January 2013 through December 2014 was Deputy General Counsel for Actavis plc. Prior to such time, Mr. LaRocca served as Divisional Counsel-US Generics for both Purepac Pharmaceuticals and Alpharma Pharmaceuticals from September 2000 through December 2005. Previously, Mr. LaRocca practiced corporate and commercial law in New York with Parker Duryee Rosoff & Haft; Christie & Viener; and Webster & Sheffield. Mr. LaRocca received his B.A. from Columbia College and his J.D. from Columbia Law School.- JohnW.LaRocca自2018年2月起担任我们的总法律顾问。2015年3月至2018年1月，拉罗卡先生担任EaglePharmaceuticals，Inc.执行Vice President and General Counsel从2005年12月到2012年12月，Larocca先生担任Actavis Inc.的美洲首席法律官，从2013年1月到2014年12月，担任Actavis plc的副总法律顾问。在此之前，LaRocca从2000年9月到2005年12月担任PurePac Pharmaceuticals和Alpharma Pharmaceuticals美国仿制药部门法律顾问。此前，LaRocca先生与Parker Duryee Rosoff&Haft；Christie&Viener；和Webster&Sheffield在纽约实践公司法和商业法。LaRocca先生在哥伦比亚学院（Columbia College）获得学士学位，在哥伦比亚法学院（Columbia Law School）获得法学博士学位。
- John W. LaRocca has served as our General Counsel since February 2018. From March 2015 through January 2018 Mr. LaRocca served as Executive Vice President and General Counsel for Eagle Pharmaceuticals, Inc. From December 2005 through December 2012 Mr. LaRocca was Chief Legal Officer for the Americas for Actavis Inc. and from January 2013 through December 2014 was Deputy General Counsel for Actavis plc. Prior to such time, Mr. LaRocca served as Divisional Counsel-US Generics for both Purepac Pharmaceuticals and Alpharma Pharmaceuticals from September 2000 through December 2005. Previously, Mr. LaRocca practiced corporate and commercial law in New York with Parker Duryee Rosoff & Haft; Christie & Viener; and Webster & Sheffield. Mr. LaRocca received his B.A. from Columbia College and his J.D. from Columbia Law School.
- David A. Hollander
David A.Hollander自2019年11月起担任我们的首席研究与开发官。Hollander博士于2006年在Allergan开始了他的行业生涯，担任眼科医疗总监，他还担任过多个领导职务，包括负责美国医疗事务的眼科护理Vice President、Vice President和全球医疗事务的眼科护理主管，以及眼前节和消费性眼部护理临床开发的治疗区域主管。在这段时间里，Hollander博士继续看望患者，并指导居民和研究员白内障手术和角膜移植。2016年，Hollander博士加入领先的眼科合同研究组织ORA，Inc，担任首席医疗官。在ORA期间，Hollander博士监督制药和设备临床开发，临床前研究以及进入新的监管终点的研究与开发的医疗操作，最显著的是开发用于评估遗传性视网膜疾病治疗的新型移动性课程。Hollander博士在斯坦福大学（Stanford University）以优异的成绩获得化学学士学位，并在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）获得医学学位。Hollander博士还在宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）获得医疗保健管理工商管理硕士学位。
David A. Hollander has served as our Chief Research and Development Officer since November 2019. Dr. Hollander began his career in industry in 2006 at Allergan as a Medical Director of Ophthalmology where he also held a number of leadership roles including Vice President of Eye Care for US Medical Affairs, Vice President and Head of Eye Care for Global Medical Affairs, as well as Therapeutic Area Head in Clinical Development for Anterior Segment and Consumer Eye Care. During this time, Dr. Hollander continued to see patients and instruct residents and fellows in cataract surgery and corneal transplantation. In 2016 Dr. Hollander joined Ora, Inc, the leading ophthalmic Contract Research Organization, as Chief Medical Officer. While at Ora, Dr. Hollander oversaw medical operations across pharmaceutical and device clinical development, preclinical studies, as well as research and development into new regulatory endpoints, most notably the development of novel mobility courses for evaluating treatments for inherited retinal diseases. Dr. Hollander received his B.S. in chemistry with honors and distinction from Stanford University, and earned his medical degree at the University of Pennsylvania School of Medicine. Dr. Hollander also obtained an M.B.A. in Health Care Management from the Wharton School at the University of Pennsylvania.- David A.Hollander自2019年11月起担任我们的首席研究与开发官。Hollander博士于2006年在Allergan开始了他的行业生涯，担任眼科医疗总监，他还担任过多个领导职务，包括负责美国医疗事务的眼科护理Vice President、Vice President和全球医疗事务的眼科护理主管，以及眼前节和消费性眼部护理临床开发的治疗区域主管。在这段时间里，Hollander博士继续看望患者，并指导居民和研究员白内障手术和角膜移植。2016年，Hollander博士加入领先的眼科合同研究组织ORA，Inc，担任首席医疗官。在ORA期间，Hollander博士监督制药和设备临床开发，临床前研究以及进入新的监管终点的研究与开发的医疗操作，最显著的是开发用于评估遗传性视网膜疾病治疗的新型移动性课程。Hollander博士在斯坦福大学（Stanford University）以优异的成绩获得化学学士学位，并在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）获得医学学位。Hollander博士还在宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）获得医疗保健管理工商管理硕士学位。
- David A. Hollander has served as our Chief Research and Development Officer since November 2019. Dr. Hollander began his career in industry in 2006 at Allergan as a Medical Director of Ophthalmology where he also held a number of leadership roles including Vice President of Eye Care for US Medical Affairs, Vice President and Head of Eye Care for Global Medical Affairs, as well as Therapeutic Area Head in Clinical Development for Anterior Segment and Consumer Eye Care. During this time, Dr. Hollander continued to see patients and instruct residents and fellows in cataract surgery and corneal transplantation. In 2016 Dr. Hollander joined Ora, Inc, the leading ophthalmic Contract Research Organization, as Chief Medical Officer. While at Ora, Dr. Hollander oversaw medical operations across pharmaceutical and device clinical development, preclinical studies, as well as research and development into new regulatory endpoints, most notably the development of novel mobility courses for evaluating treatments for inherited retinal diseases. Dr. Hollander received his B.S. in chemistry with honors and distinction from Stanford University, and earned his medical degree at the University of Pennsylvania School of Medicine. Dr. Hollander also obtained an M.B.A. in Health Care Management from the Wharton School at the University of Pennsylvania.
- Vicente Anido, Jr.
自2013年2月，Vicente Anido, Jr.担任公司董事。目前，他是Aerie Pharmaceuticals主席兼首席执行官，一家上市发展阶段公司，其集中在眼科领域。他是Ista Pharmaceuticals的前任总裁、首席执行官兼董事，该公司成立于2012年。在加入Ista Pharmaceuticals之前，从2000年到2001年，他担任Windamere Venture Partners的普通合伙人。从1996年到1999年，他担任CombiChem的总裁兼首席执行官，一家药物发现公司。从1993年到1996年，他担任Allergan美国地区总裁，负责北美和南美的商业运作。加入Allergan之前，他在Marion Laboratories and Marion Merrell Dow工作17年，包括Marion美国处方产品部门的业务管理副总裁。
Vicente Anido, Jr. has served as our Chief Executive Officer since July 2013 and as Chairman of our Board since April 2013. Dr. Anido is the former President, Chief Executive Officer and Director of ISTA Pharmaceuticals, Inc., which was acquired by Bausch + Lomb, Inc. in 2012. Prior to joining ISTA Pharmaceuticals, Dr. Anido served as General Partner of Windamere Venture Partners from 2000 to 2001. From 1996 to 1999 Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company. From 1993 to 1996 Dr. Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan’s commercial operations for North and South America. Prior to joining Allergan, Dr. Anido spent 17 years at Marion Laboratories and Marion Merrell Dow, Inc., including as Vice President, Business Management of Marion’s U.S. Prescription Products Division. Dr. Anido previously served as a member of the board of directors of QLT Inc. from 2012 to 2013 Depomed, Inc. from February 2013 to May 2016 and Nicox S.A. from June 2013 to June 2014. In addition, from 2002 to 2008 Dr. Anido served as a member of the board of directors of Apria Healthcare, Inc. Dr. Anido holds a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City.- 自2013年2月，Vicente Anido, Jr.担任公司董事。目前，他是Aerie Pharmaceuticals主席兼首席执行官，一家上市发展阶段公司，其集中在眼科领域。他是Ista Pharmaceuticals的前任总裁、首席执行官兼董事，该公司成立于2012年。在加入Ista Pharmaceuticals之前，从2000年到2001年，他担任Windamere Venture Partners的普通合伙人。从1996年到1999年，他担任CombiChem的总裁兼首席执行官，一家药物发现公司。从1993年到1996年，他担任Allergan美国地区总裁，负责北美和南美的商业运作。加入Allergan之前，他在Marion Laboratories and Marion Merrell Dow工作17年，包括Marion美国处方产品部门的业务管理副总裁。
- Vicente Anido, Jr. has served as our Chief Executive Officer since July 2013 and as Chairman of our Board since April 2013. Dr. Anido is the former President, Chief Executive Officer and Director of ISTA Pharmaceuticals, Inc., which was acquired by Bausch + Lomb, Inc. in 2012. Prior to joining ISTA Pharmaceuticals, Dr. Anido served as General Partner of Windamere Venture Partners from 2000 to 2001. From 1996 to 1999 Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company. From 1993 to 1996 Dr. Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan’s commercial operations for North and South America. Prior to joining Allergan, Dr. Anido spent 17 years at Marion Laboratories and Marion Merrell Dow, Inc., including as Vice President, Business Management of Marion’s U.S. Prescription Products Division. Dr. Anido previously served as a member of the board of directors of QLT Inc. from 2012 to 2013 Depomed, Inc. from February 2013 to May 2016 and Nicox S.A. from June 2013 to June 2014. In addition, from 2002 to 2008 Dr. Anido served as a member of the board of directors of Apria Healthcare, Inc. Dr. Anido holds a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City.
- Casey C. Kopczynski
Casey C. Kopczynski，从2005年参与创办本公司开始，担任本公司首席科学官。2002-2005，他是 Biotech Initiative, LLC的管理合伙人，这是一个于服务于新兴生物技术公司的咨询公司。2003-2004，他曾任Ercole Biotech的研究部副总裁，该公司开发用于治疗癌症，炎症和罕见遗传性疾病的药物。加入Ercole Biotech之前，1996-2002，他是Exelixis, Inc的研究主管，及其科研人员团队的创始成员。他获得了印第安那大学分子、细胞与发育生物学的博士学位，也曾是加州大学伯克利分校Jane Coffin Childs 研究员。
Casey C. Kopczynski has served as our Chief Scientific Officer since co-founding our company in 2005. From 2002 to 2005 Dr. Kopczynski was the Managing Partner at Biotech Initiative, LLC, a consulting practice dedicated to emerging biotech companies. Dr. Kopczynski was also previously the Vice President of Research at Ercole Biotech, Inc. from 2003 to 2004 a company developing drugs for the treatment of cancer, inflammation and orphan genetic diseases. Prior to Ercole Biotech, Inc., Dr. Kopczynski was Director of Research and a founding member of the scientific staff at Exelixis, Inc. from 1996 to 2002. Dr. Kopczynski received his Ph.D. in Molecular, Cellular and Developmental Biology from Indiana University and was a Jane Coffin Childs Research Fellow at the University of California, Berkeley.- Casey C. Kopczynski，从2005年参与创办本公司开始，担任本公司首席科学官。2002-2005，他是 Biotech Initiative, LLC的管理合伙人，这是一个于服务于新兴生物技术公司的咨询公司。2003-2004，他曾任Ercole Biotech的研究部副总裁，该公司开发用于治疗癌症，炎症和罕见遗传性疾病的药物。加入Ercole Biotech之前，1996-2002，他是Exelixis, Inc的研究主管，及其科研人员团队的创始成员。他获得了印第安那大学分子、细胞与发育生物学的博士学位，也曾是加州大学伯克利分校Jane Coffin Childs 研究员。
- Casey C. Kopczynski has served as our Chief Scientific Officer since co-founding our company in 2005. From 2002 to 2005 Dr. Kopczynski was the Managing Partner at Biotech Initiative, LLC, a consulting practice dedicated to emerging biotech companies. Dr. Kopczynski was also previously the Vice President of Research at Ercole Biotech, Inc. from 2003 to 2004 a company developing drugs for the treatment of cancer, inflammation and orphan genetic diseases. Prior to Ercole Biotech, Inc., Dr. Kopczynski was Director of Research and a founding member of the scientific staff at Exelixis, Inc. from 1996 to 2002. Dr. Kopczynski received his Ph.D. in Molecular, Cellular and Developmental Biology from Indiana University and was a Jane Coffin Childs Research Fellow at the University of California, Berkeley.
- Thomas A. Mitro
Thomas A. Mitro，自2013年8月起担任本公司总裁兼首席营运官。从2012年11月至2013年8月，他担任 Omeros Corporation销售与营销副总裁，这是一个临床阶段的生物制药公司。在此之前，2002年7月至2012年7月，他担任ISTA Pharmaceuticals 销售与营销副总裁，当时帮助建立了公司的商业运作模式，推出了一些眼部护理产品，其中包括Bromday溴芬酸滴眼液0.09和Bepreve（贝他斯汀斯汀滴眼液）1.5。此前，他在Allergan, Inc担任了多个职位，其中包括皮肤处理部副总裁；业务开发部副总裁；电子商务副总裁。 他获得了迈阿密大学的理科学士学位。
Thomas A. Mitro has served as our President and Chief Operating Officer since August 2013. From November 2012 to August 2013 Mr. Mitro served as Vice President, Sales and Marketing at Omeros Corporation, a clinical-stage biopharmaceutical company. Prior to this, Mr. Mitro was Vice President, Sales and Marketing at ISTA Pharmaceuticals from July 2002 to July 2012 where he was instrumental in building ISTA’s commercial operations and launching several eye-care products, including Bromday bromfenac ophthalmic solution 0.09 and Bepreve (bepotastine besilate ophthalmic solution) 1.5. Previously, Mr. Mitro held various positions at Allergan, Inc., including Vice President, Skin Care; Vice President, Business Development; and Vice President, e-Business. Mr. Mitro received his B.S. from Miami University.- Thomas A. Mitro，自2013年8月起担任本公司总裁兼首席营运官。从2012年11月至2013年8月，他担任 Omeros Corporation销售与营销副总裁，这是一个临床阶段的生物制药公司。在此之前，2002年7月至2012年7月，他担任ISTA Pharmaceuticals 销售与营销副总裁，当时帮助建立了公司的商业运作模式，推出了一些眼部护理产品，其中包括Bromday溴芬酸滴眼液0.09和Bepreve（贝他斯汀斯汀滴眼液）1.5。此前，他在Allergan, Inc担任了多个职位，其中包括皮肤处理部副总裁；业务开发部副总裁；电子商务副总裁。 他获得了迈阿密大学的理科学士学位。
- Thomas A. Mitro has served as our President and Chief Operating Officer since August 2013. From November 2012 to August 2013 Mr. Mitro served as Vice President, Sales and Marketing at Omeros Corporation, a clinical-stage biopharmaceutical company. Prior to this, Mr. Mitro was Vice President, Sales and Marketing at ISTA Pharmaceuticals from July 2002 to July 2012 where he was instrumental in building ISTA’s commercial operations and launching several eye-care products, including Bromday bromfenac ophthalmic solution 0.09 and Bepreve (bepotastine besilate ophthalmic solution) 1.5. Previously, Mr. Mitro held various positions at Allergan, Inc., including Vice President, Skin Care; Vice President, Business Development; and Vice President, e-Business. Mr. Mitro received his B.S. from Miami University.
- Richard J. Rubino
Richard J. Rubino，自2012年10月起担任本公司首席财务官。从2008年3月至2012年4月，他担任Medco Health Solutions的高级财务副总裁兼首席财务官；从1993年5月至2008年3月，担任财务总管，及规划副总裁，负责财务，业务和战略规划。此前，他曾任职于IBM（1983年至1993年5月）和普华永道（1979-1983，原普华公司），并担任了多个职位。他是一名注册会计师，也是美国注册会计师协会成员。他获得了曼哈顿学院的会计学士学位。他自2009年起，成为Northside Center for Child Development的董事，2012年起担任财务总管，目前还是其财务委员会的成员。
Richard J. Rubino has served as our Chief Financial Officer since October 2012. From March 2008 to April 2012 Mr. Rubino served as Senior Vice President, Finance and Chief Financial Officer of Medco Health Solutions, Inc. and from May 1993 to March 2008 served as Controller, Chief Accounting Officer and Vice President of Planning. Previously, Mr. Rubino held various positions at International Business Machines Corporation from 1983 to May 1993 and PricewaterhouseCoopers LLP formerly Price Waterhouse & Co. from 1979 to 1983. Mr. Rubino received his B.S. in Accounting from Manhattan College. He has been a director of the Northside Center for Child Development since 2009 the Board Treasurer from 2012 through 2016 and became Board President in 2016. He also currently serves as a member of the Finance Committee and Executive Committee.- Richard J. Rubino，自2012年10月起担任本公司首席财务官。从2008年3月至2012年4月，他担任Medco Health Solutions的高级财务副总裁兼首席财务官；从1993年5月至2008年3月，担任财务总管，及规划副总裁，负责财务，业务和战略规划。此前，他曾任职于IBM（1983年至1993年5月）和普华永道（1979-1983，原普华公司），并担任了多个职位。他是一名注册会计师，也是美国注册会计师协会成员。他获得了曼哈顿学院的会计学士学位。他自2009年起，成为Northside Center for Child Development的董事，2012年起担任财务总管，目前还是其财务委员会的成员。
- Richard J. Rubino has served as our Chief Financial Officer since October 2012. From March 2008 to April 2012 Mr. Rubino served as Senior Vice President, Finance and Chief Financial Officer of Medco Health Solutions, Inc. and from May 1993 to March 2008 served as Controller, Chief Accounting Officer and Vice President of Planning. Previously, Mr. Rubino held various positions at International Business Machines Corporation from 1983 to May 1993 and PricewaterhouseCoopers LLP formerly Price Waterhouse & Co. from 1979 to 1983. Mr. Rubino received his B.S. in Accounting from Manhattan College. He has been a director of the Northside Center for Child Development since 2009 the Board Treasurer from 2012 through 2016 and became Board President in 2016. He also currently serves as a member of the Finance Committee and Executive Committee.